Bio Labs USA, INC
Bio Labs USA, INC was paid $664K by Medicaid between Jan 2018 and Sep 2024, across 53 billing codes. Its largest line is G0480, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed — 38% of everything it billed.
LINDEN, NJ 07036
Next to other Clinical Medical Laboratory providers in New Jersey
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 20,569 | $414K | |
| 2019 | 6,013 | $179K | |
| 2020 | 392 | $21K | |
| 2021 | 417 | $24K | |
| 2022 | 444 | $26K | |
| 2024incomplete | 89 | $146.80 |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 38% | 2,917 | 2,242 | $252K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 36% | 3,907 | 3,024 | $238K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 7.5% | 861 | 806 | $50K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 3.3% | 1,070 | 1,069 | $22K |
| 80061 | Lipid panel | 1.8% | 1,186 | 1,184 | $12K |
| 80050 | General health panel | 1.7% | 324 | 324 | $11K |
| 82607 | 1.4% | 907 | 907 | $9K | |
| 84480 | 1.3% | 799 | 799 | $9K | |
| 82728 | 1.1% | 709 | 709 | $7K | |
| 82746 | <1% | 891 | 891 | $6K | |
| 84439 | <1% | 815 | 815 | $6K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,068 | 1,064 | $5K |
41 more codes
| 82570 | <1% | 1,718 | $4K | |
| 80053 | Comprehensive metabolic panel | <1% | 604 | $4K |
| 83550 | <1% | 694 | $3K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 634 | $2K |
| 83540 | <1% | 696 | $2K | |
| 86038 | <1% | 285 | $2K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,338 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 188 | $1K |
| 85044 | <1% | 668 | $1K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 32 | $1K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 32 | $1K |
| 86431 | <1% | 301 | $1K | |
| 86803 | <1% | 64 | $1K | |
| 86703 | <1% | 65 | $932.03 | |
| 86060 | <1% | 313 | $894.40 | |
| 82043 | <1% | 319 | $850.25 | |
| 86706 | <1% | 80 | $826.29 | |
| 86140 | <1% | 347 | $813.44 | |
| 87340 | <1% | 65 | $753.62 | |
| 81001 | <1% | 813 | $750.86 | |
| 86704 | <1% | 47 | $606.46 | |
| 83655 | <1% | 67 | $594.00 | |
| 84550 | <1% | 278 | $589.64 | |
| 86708 | <1% | 48 | $505.48 | |
| 85651 | <1% | 354 | $428.36 | |
| 87168 | <1% | 90 | $420.08 | |
| 84153 | <1% | 22 | $319.32 | |
| 86738 | <1% | 12 | $288.00 | |
| 84436 | <1% | 785 | $273.00 | |
| 84154 | <1% | 18 | $269.97 | |
| 87070 | <1% | 26 | $234.00 | |
| 86215 | <1% | 12 | $216.00 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 38 | $196.94 |
| 86592 | <1% | 61 | $95.02 | |
| 81015 | <1% | 317 | $28.00 | |
| 84479 | <1% | 742 | $21.00 | |
| 80076 | <1% | 127 | $14.00 | |
| G0431 | Drug screen, qualitative; multiple drug classes by high complexity test method (e.g., immunoassay, enzyme assay), per patient encounter | 0% | 16 | $0.00 |
| 85007 | 0% | 106 | $0.00 | |
| 84520 | 0% | 23 | $0.00 | |
| 80051 | 0% | 25 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.